Therapeutic Goods (Medicines Watch List) Determination 2018

The central concept is the “Medicines Watch List”. This is a category of reportable medicines that attracts additional regulatory attention under the Act. A “reportable medicine” is defined in subsection 3(1) of the Act (the instrument does not reproduce that definition, but it is a prerequisite). The instrument cross references the Act’s definitions of “medicine” and “reportable medicine”. The list is not a therapeutic guideline, a prescribing recommendation, or a prohibition; it is purely a reporting trigger. The instrument draws important distinctions based on route of administration. For example, the antimicrobials aciclovir, amphotericin B, chloramphenicol, ciprofloxacin, gentamicin, and metronidazole are listed only when given intravenously (IV), while rifampicin and sodium fusidate are listed either by mouth (PO) or intravenously. This specificity matters because the same drug given by a different route is not on the watch list. The definitions of “IV” and “PO” in section 4 are straightforward but critical: an oral formulation of ciprofloxacin is not caught; an intravenous formulation is.

The instrument also introduces a dynamic reference: item 5(a) captures “a vaccine included in the National Immunisation Program Schedule, as in force or existing at 1 March 2025”. This creates a moving target because the National Immunisation Program Schedule changes over time. If the schedule is updated after that date, the instrument does not automatically incorporate the change unless it is amended. As at the date of the instrument (2018), the reference to 1 March 2025 appears to be a forward looking date, which is unusual for a legislative instrument. It may represent a typographical error (perhaps 2020 or 2025 was intended to be a later date after an amendment). In practice, any vaccine added to the National Immunisation Program after 1 March 2025 would not be on the watch list unless the instrument is varied.

The categories themselves reflect an implicit risk assessment: antimicrobials where resistance is a concern; antidotes where adverse event reporting may detect supply problems or administration errors; emergency and critical care drugs which are often high alert medicines; anticoagulants with a narrow therapeutic index; vaccines subject to continuous safety monitoring; obstetric drugs with potential for maternal or fetal harm; antivenoms where alternative therapies are limited; and emergency rescue medicines (naloxone, adrenaline, salbutamol) where reporting might support overdose surveillance. The instrument does not explain why these specific medicines were selected, but the grouping supplies a useful starting point for compliance.

The immediate legal effect falls on persons who have obligations under sections 30EF and 30EG of the Act. Those sections typically require sponsors of medicines (the entities holding the Australian Register of Therapeutic Goods entry), manufacturers, wholesalers, and possibly healthcare professionals to report adverse events, supply interruptions, or other designated information to the TGA. By adding a medicine to the watch list, the instrument expands the reporting burden for that medicine. The most directly affected entities are:

• Sponsors of each medicine listed in Schedule 1. A sponsor is the entity responsible for the supply of the medicine in Australia. For a product like morphine IV, which has multiple manufacturers and branded generics, every sponsor with an ARTG entry for morphine IV becomes subject to the additional reporting obligations triggered by the watch list. This includes both originator and generic sponsors.
• Hospitals and health services that administer these medicines. Although the reporting duty under the Act may be placed on the sponsor, hospitals often have contractual or statutory duties to report adverse events to the sponsor, and the watch list may increase the frequency or detail of those reports. For items such as adrenaline IV, amiodarone IV, or heparin, which are used routinely in emergency departments and intensive care units, the administrative burden on pharmacy departments and clinical risk teams can be substantial.
• Vaccine providers and pharmaceutical companies supplying vaccines on the National Immunisation Program. The watch list catches all vaccines on that program as at 1 March 2025, which includes a large number of products (influenza, HPV, COVID 19 vaccines if added, measles mumps rubella, etc). Every sponsor of those vaccines must comply with the watch list reporting requirements.
• Community pharmacies that supply items like salbutamol inhalers, adrenaline autoinjectors, or naloxone nasal spray. While the sponsor bears primary reporting duty, pharmacists who dispense these products may need to forward adverse event reports to the sponsor. The watch list may also affect stock management obligations if supply shortages must be reported.

Indirectly, patients who use these medicines are affected insofar as enhanced reporting may lead to earlier detection of safety signals or, conversely, to reporting fatigue that diminishes the utility of the system. The instrument does not create new rights for patients to access data or seek compensation.

The instrument itself creates no duties or rights; it merely draws a line around which medicines attract duties under the Act. The key duties arise from sections 30EF and 30EG, which are not set out in this instrument. Based on the structure of Part 3A of the Therapeutic Goods Act, those sections likely impose obligations on responsible persons (typically sponsors) to report certain adverse events, defective products, or other safety information to the Secretary. The watch list broadens the scope of what must be reported for the medicines listed.

For example, section 30EF(2) may require a person to report “reportable adverse events” in relation to a watch list medicine within a specified period, or section 30EG(2) might require reporting of “serious adverse events” or product defects. The instrument’s explanation says it is made for the purposes of those subsections, implying that without the determination, the reporting obligation would not apply or would be narrower.

The principal duty that flows from the instrument is therefore an enhanced duty of proactive pharmacovigilance. Sponsors must monitor their products for adverse events, even those that would not ordinarily be reportable for medicines not on the watch list. This may include lower severity events, or events that occur at a lower threshold. The instrument also creates a duty to keep abreast of updates to the watch list itself; if a medicine is added or a route specification changes, sponsors must adjust their reporting systems accordingly.

Rights under the instrument are limited. A sponsor or health professional may have a right to request the TGA to remove a medicine from the watch list, but the instrument does not provide a mechanism for that. There may be an implied right to be notified of changes, but the instrument does not impose a public consultation requirement. The Instrument is made under delegated legislation and can be altered at ministerial discretion without parliamentary debate, subject to disallowance by the Senate. From a free market perspective, this confers significant discretion on the regulator with limited transparency about the criteria for inclusion or removal.

The instrument states no penalties. Penalties for non compliance with the underlying reporting obligations reside in the Therapeutic Goods Act. They are likely civil penalty provisions, with maximum penalties expressed in penalty units (currently $330 per unit for an individual, $1,650 per unit for a body corporate). A failure to report a reportable adverse event for a watch list medicine could attract a penalty of perhaps 50 to 200 penalty units depending on the specific subsection. The instrument effectively increases the number of events that must be reported, thereby expanding the potential for penalty exposure.

Enforcement is by the TGA, which may issue infringement notices, accept enforceable undertakings, or institute civil proceedings in the Federal Court. The TGA may also refer matters for criminal prosecution if there is evidence of deliberate concealment or fraud, but the watch list itself does not create criminal offences. The practical enforcement risk is that the TGA can allege a breach of the Act by pointing to a failure to report an adverse event for a watch list medicine, even if the event was not obviously serious. This shifts the burden onto the sponsor to justify non reporting.

Because the instrument is a legislative instrument, it is legally enforceable. A court would interpret it according to its plain words. The specific route designations (IV, PO) and the list of antimicrobial agents by name create bright line rules. If a sponsor supplies a product that is caught by the words of Schedule 1, ignorance of the watch list is no defence to a penalty for failing to report. The instrument therefore imposes a strict liability framework: the only question is whether the medicine matches the Schedule, not whether the sponsor knew it was on the list.

The Medicines Watch List Determination operates within the broader regulatory framework of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. It supplements the usual adverse event reporting requirements that apply to all medicines by designating a subset for heightened surveillance. It does not override other laws; it adds a layer. For example:

• The Poisons Standard (Poisons Standard 2025, or as amended) schedules certain medicines as prescription only or controlled. Many watch list medicines like morphine IV, diazepam IV, or ketamine (not listed) are also scheduled drugs. The watch list does not affect scheduling; it only affects reporting. A pharmacy already subject to state poisons legislation must also comply with federal reporting triggers.
• State and territory health legislation often mandates reporting of adverse events for certain scheduled medicines or for incidents in public hospitals. These duties exist independently. The watch list may create dual reporting obligations: one under state health incident management systems and another under the TGA Act. This can lead to duplication, confusion, and increased compliance costs, especially for smaller hospitals or remote health services.
• Privacy laws (Privacy Act 1988) and state health records legislation govern the collection and use of patient information. Reporting adverse events for watch list medicines may require the sponsor to collect identifiable patient data. The instrument does not provide any exemption or safe harbour for privacy compliance, so sponsors must navigate overlapping legal regimes.
• The Therapeutic Goods (Medical Devices) Act is separate; the watch list covers only medicines, not devices. However, some medicines on the list (e.g., adrenaline autoinjectors, naloxone nasal spray) may be classified as combination products or as medicines in a delivery device. The line between medicine and device can be blurry, and the watch list catches the medicine component.

The instrument interacts with the National Immunisation Program (NIP) Schedule in a peculiar way: it incorporates by reference the NIP Schedule as at a specific date (1 March 2025). If the NIP Schedule is amended, the watch list does not automatically update. This creates a potential gap: a vaccine added to the NIP after 1 March 2025 would not be on the watch list unless the instrument is amended, even though the policy rationale (heightened surveillance of vaccines) would apply equally. This is a legislative drafting oddity that creates uncertainty.

The instrument as provided shows no amendment history. It is titled “Determination 2018” and is the original version made in 2018. There are no registered amendments listed in the instrument text. However, the reference to “1 March 2025” in item 5(a) suggests that the instrument may have been varied at some point to include that date, because it would be highly unusual for a 2018 instrument to reference a date seven years in the future. It is more likely that the instrument has been amended at least once, but the version supplied to the user does not include a compilation history or explanation of amendments. Alternatively, the date may be a typographical error for “1 March 2020” or a similar date. In a commercial compliance context, it is essential to check the Federal Register of Legislation for the current compiled version of the instrument, including any amendments, to confirm the exact text of item 5 and to see whether other medicines have been added or removed since 2018.

The instrument was made on an unknown date in 2018 and commenced on the day after registration. It has likely been varied by later determining instruments under s 30EJ, such as the Therapeutic Goods (Medicines Watch List) Amendment Determination 2020 or 2023, but those are not mentioned here. A prudent compliance professional would verify the entire Schedule against the current compilation before assuming that the list here is exhaustive.

This instrument has not been the subject of any reported litigation that is publicly known as of the date of analysis. There are no Federal Court or Administrative Appeals Tribunal decisions interpreting the Medicines Watch List, or challenging the validity of the determination. Given the instrument’s technical nature and the fact that it merely designates medicines rather than imposing direct obligations, litigation is unlikely unless a reporting penalty is contested on the basis that the particular medicine does not fall within the words of Schedule 1. For example, a dispute could arise over the meaning of “IV” for a drug that is administered intravenously in a minibag versus an IV push, or over whether a particular derivative of an antimicrobial is “a medicine that contains” the listed agent. Such interpretive cases are rare because the liability rests on the clear words of the list.

There is also the possibility of an indirect challenge: a sponsor penalised for failing to report an adverse event for a watch list medicine might argue that the determination was ultra vires the Act because the minister exercised the power under s 30EJ in a way that was not reasonably capable of being related to the purpose of the reporting provisions. This would require a merits review or judicial review action. No such case has been reported. The instrument has operated largely as a ministerial tool for focusing surveillance resources.

Several aspects of the instrument can trap the unwary:

1. Route specificity: Many antimicrobials are listed only for the intravenous route. A sponsor who supplies the same drug in an oral or intramuscular formulation might mistakenly believe their product is not on the watch list. But if the sponsor also supplies the IV form, they are caught. For example, a company selling both ciprofloxacin tablets and ciprofloxacin injection must report adverse events only for the injection, not the tablets. This creates a compliance system that must differentiate by dosage form and route.

2. The “contains” language: Item 1 lists “medicines that contain any of the following antimicrobial agents”. This is broad enough to capture fixed dose combinations that include the listed agent. For instance, piperacillin and tazobactam is explicitly listed, but a combination product containing ampicillin and another drug would be caught if it contains ampicillin. Similarly, any medicine containing vancomycin, whether as a single ingredient or in a mixture, is on the watch list. This extends the net beyond the obvious single ingredient injectables.

3. Vaccine ambiguity: Item 5(a) references “a vaccine included in the National Immunisation Program Schedule, as in force or existing at 1 March 2025”. If the NIP Schedule has been amended since that date, there is a risk that some vaccines currently on the program are not on the watch list, even though they should logically be subject to the same reporting. Conversely, a vaccine that was on the NIP at 1 March 2025 but later removed may still be on the watch list. This frozen reference creates a compliance trap for sponsors who assume the watch list tracks the current NIP.

4. Common emergency drugs: Item 3 includes adrenaline IV, morphine IV, noradrenaline, salbutamol IV, and hydrocortisone IV. These are ubiquitous in hospital crash carts and intensive care units. The reporting burden falls on the sponsors of these products, many of which are low cost generics with thin margins. The cost of maintaining pharmacovigilance systems for a small generic company may significantly outweigh the revenue from the product. This is a hidden cost of the watch list that may discourage the supply of generic injectables.

5. Antivenoms: Item 7 lists 11 specific antivenoms. Some of these are manufactured by a single supplier (e.g., CSL Seqirus). The sponsor must have robust reporting systems for these niche products, even though the number of adverse events may be very low. Over reporting of minor events due to zero risk tolerance can clog the system.

6. Overlap with other lists: Some medicines on this watch list also appear on the TGA’s “High Risk Medicines” list or “Medicines Subject to Additional Monitoring”. Compliance with one list does not mean compliance with the other. Each list has distinct reporting triggers and time frames.

Compliance with the Medicines Watch List Determination begins with determining whether your organisation is a sponsor of a medicine listed in Schedule 1. The first step is to compile a complete inventory of all medicines supplied in Australia, by generic name, trade name, active ingredient, dosage form, strength, and route of administration. Map each product against the items in Schedule 1. For vaccines, check the version of the National Immunisation Program Schedule that was in force at 1 March 2025 (or the current compiled date if the instrument has been amended). This mapping should be documented and kept current whenever the watch list changes.

Once a product is identified as being on the watch list, the sponsor must establish procedures to comply with the reporting obligations under sections 30EF and 30EG of the Act. These obligations likely require reporting of adverse events within a specified period (e.g., 15 days for serious events, 90 days for non serious). The sponsor must train staff in pharmacovigilance to recognise reportable events and to file eReports through the TGA’s online portal. For small sponsors, this may necessitate outsourcing to a contract pharmacovigilance provider. For hospitals that are not sponsors but that administer these medicines, compliance involves ensuring that adverse event reports are forwarded promptly to the sponsor. Hospital pharmacy departments should create standard operating procedures for watch list medicines, including flagging them in electronic medication management systems.

Record keeping is crucial. The Therapeutic Goods Act requires sponsors to maintain records of adverse events and to make them available to the TGA on request. The watch list expands the volume of records. Sponsors should audit their adverse event databases regularly to identify any missing reports. They should also monitor the TGA website for amendments to the Medicines Watch List Determination. Because the instrument can be changed by a new determination without prior notice, a sponsor should subscribe to the TGA’s legislative instrument alerts or check the Federal Register of Legislation monthly.

Finally, larger sponsors may choose to engage with the TGA through the Medicines Watch List consultation process if it exists (the instrument does not create one, but the TGA may accept submissions). If a medicine is on the list and the sponsor believes the reporting burden is disproportionate, they can make a case for removal. Until then, compliance is mandatory and the safest approach is to report all potential adverse events for watch list medicines, erring on the side of inclusion, to avoid penalty exposure.